Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Basel | OTHER |
Not provided
Not provided
Not provided
Not provided
In this trial the researchers plan to recruit 25,000 volunteers to be randomly allocated either wearing sunglasses or ordinary glasses in public spaces where they are close to other people, or not wear glasses in such circumstances. For each participant the trial period is 2 weeks, after which they will be asked to complete a brief questionnaire which includes questions about results of COVID-19 tests during the trial period.
A systematic review of observational studies indicated that eye protection may be an effective measure to prevent SARS-CoV-2 infections. Randomized trials are needed to assess whether the observed associations are caused by protection of the eye or confounding factors such as other systematic differences between users and non-users of eye protection, co-interventions, or changes in COVID-19 incidence when comparisons were done over time.
This is a pragmatic, virtual, parallel group, 1:1 randomized, superiority trial. The researchers will recruit and randomize participants via an online portal. The trial will be fully remote and virtual without any personal interaction between investigators and participants. All members of the public are eligible who confirm that they are at least 18 years of age, do not regularly wear glasses, have not contracted COVID-19 since December 15th 2021, and are willing to be randomized to wear, or not wear glasses in public when close to other people, for a 2-week period. Persons who are dependent on visual aids but typically use contact lenses are eligible. The participants will be randomized (1:1) to wear glasses (sunglasses or other types of glasses) in public spaces when close to others (public transport, shopping centers etc.), or to the control group. The control group will be asked not to wear glasses in public spaces when close to others. The primary outcome is positive test for COVID-19.
The researchers aim to include about 25,000 participants to have a statistical power of 80% to detect a relative risk reduction of 25% for the primary outcome.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glasses | Experimental | Participants in the experimental arm are asked to wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.). |
|
| Not glasses | No Intervention | Participants in no interventions arm are asked to not wear glasses (sunglasses or other glasses) when outside their home and close to others (e.g. on public transport, in shopping centres etc.). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Wearing glasses (any type) | Behavioral | Participants are asked to wear glasses in public spaces. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Positive test for SARS-CoV-2 | The investigators will compare the incidence of notified cases of COVID-19 (i.e. registered positive SARS-CoV-2 tests). | Days 3 to 17 after start of trial period. |
| Measure | Description | Time Frame |
|---|---|---|
| Health care use for respiratory symptoms | Routinely collected data (Norwegian Registry for Primary Health Care (KPR) and Norwegian Patient Registry (NPR) databases) | Day 1 to 28 |
| Health care use for injuries health care use (all causes) from day 1 to day 21 (data source: KPR and NPR |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Atle Fretheim, PhD | Head of Centre for Epidemic Interventions Research (CEIR) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Norwegian Institute of Public Health | Oslo | 0213 | Norway |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36454571 | Result | Fretheim A, Elgersma IH, Helleve A, Elstrom P, Kacelnik O, Hemkens LG. Effect of Wearing Glasses on Risk of Infection With SARS-CoV-2 in the Community: A Randomized Clinical Trial. JAMA Netw Open. 2022 Dec 1;5(12):e2244495. doi: 10.1001/jamanetworkopen.2022.44495. |
Not provided
Not provided
From protocol:
The researchers intend to give full access to the full protocol, participant-level dataset, and statistical code, to anyone who is interested, after securing that the dataset is fully anonymized.
The investigators expect to be able to share unidentifiable dataset with partners inside the European Union (EU) by May 2022, and an anonymous dataset for wide distribution at a later stage.
Data that are not fully anonymized will only be shared within the EU (due to data protection regulations).
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D012141 | Respiratory Tract Infections |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D007239 | Infections |
| D014777 | Virus Diseases |
Not provided
Not provided
Sequence generation We will use a simple 1:1 randomization by means of computer-generated random numbers.
The allocation will be concealed as the participant themselves will be directly informed of their allocation as soon as they have agreed to take part in the trial and have completed the online consent form. Generation of allocation sequence, enrolment of participants and assignment of participants will all be handled by the digital recruitment platform.
Not provided
Not provided
No blinding was feasible, except for in the analysis phase. One member of our team (A.H.) provided the chief analyst (I.H.E.) with a data file in which group allocation was blinded. The chief analyst presented the main results to the project team members, who were also blinded to the group allocation (and data on use of glasses). We discussed how we would interpret the findings depending on whether one group or the other was the intervention group, and we prepared a short report that we posted online before unblinding ourselves to the group allocation.
Not provided
Routinely collected data (KPR and NPR databases) |
| Day 1 to 21 |
| Health care use (all causes) | Routinely collected data (KPR and NPR databases) | Day 1 to 21 |
| Any positive COVID-19 test result | Self report | Day 1 to 17 |
| Respiratory symptoms | Self report | Day 1 to 17 |
| Health care use for respiratory symptoms | Self report | Day 1 to 17 |
| Health care use for injuries | Self report | Day 1 to 17 |
| Health care use (all causes) | Self report | Day 1 to 17 |
| D018352 |
| Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |